Corcept Therapeutics Incorporated Common Stock (NASDAQ: CORT)
According to the Complaint, Corcept is a pharmaceutical company that purports to develop medications to treat
severe metabolic, oncologic, and psychiatric disorders by modulating the effect of cortisol. Korlym is the Company’s drug that has been approved by the FDA to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome.